# Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

> **NCT03361735** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Leuprolide Acetate
- **DRUG:** Goserelin Acetate
- **RADIATION:** Stereotactic Body Radiation Therapy
- **RADIATION:** Radium Ra 223 Dichloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT03361735
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-29
- **Primary completion:** 2024-03-21
- **Final completion:** 2027-01-06
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03361735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03361735, "Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03361735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*